Content Conference Coverage Conferences AASLD 2015
AASLD 2015: REP 2139 Shows Promise for People with Hepatitis B and Hepatitis Delta Coinfection
- Details
- Category: Experimental HBV Drugs
- Created on Sunday, 15 November 2015 00:00
The nucleic acid-based polymer REP 2139, used first as monotherapy then combined with pegylated interferon, reduced hepatitis B surface antigen (HBsAg) levels, lowered hepatitis delta viral load, and increased anti-HBs antibody titers, according to findings from a small Phase 2 study presented at the AASLD Liver Meeting taking place this week in San Francisco. Participants fell into 2 distinct groups, with half being partial responders and half full responders.
AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD
- Details
- Category: Fibrosis & Cirrhosis
- Created on Wednesday, 25 November 2015 00:00
Drinking coffee was associated with lower liver stiffness -- a non-invasive measure used to estimate liver fibrosis -- in people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD), researchers reported at the 2015 AASLD Liver Meeting last week in San Francisco. The study also showed a trend toward less liver fat build-up in people with NAFLD.
AASLD 2015: U.S. Faces Biggest Burden of Hepatitis C Treatment Costs Before 2020
- Details
- Category: HCV Treatment
- Created on Wednesday, 09 December 2015 00:00
The cost of treating hepatitis C is likely to decline dramatically over the next decade in the U.S., not because of cuts in drug prices, but because the population in need of treatment will shrink by 2020 as a majority of patients will already have been treated, according to research by Jagpreet Chhatwal of Massachusetts General Hospital and colleagues presented at the AASLD Liver Meeting in San Francisco last month.
AASLD 2015: Tenofovir During Pregnancy Reduces Risk of Mother-to-Child Hepatitis B Transmission
- Details
- Category: Pregnancy & HBV MTCT
- Created on Thursday, 19 November 2015 00:00
Women with chronic hepatitis B and high viral load who were treated with tenofovir (Viread) during pregnancy were significantly less likely to transmit hepatitis B virus (HBV) to their babies, according to study findings presented this week at the AASLD Liver Meeting in San Francisco. Another study showed that women with hepatitis B often experience viral load or ALT "flares" during pregnancy or post-partum.
AASLD 2015: Study Reveals Potential Challenges for Scaling Up Hepatitis C Therapy in the UK
- Details
- Category: HCV Treatment
- Created on Wednesday, 25 November 2015 00:00
A large proportion of people with chronic hepatitis C virus (HCV) infection in the UK have comorbidities, hazardous use of drugs and alcohol, and are taking medications that could potentially interact with HCV direct-acting antivirals (DAAs), according to research presented at the 2015 AASLD Liver Meeting in San Francisco. The investigators caution that clinicians "need to be aware" of the potential for interactions when choosing HCV treatment regimens.
More Articles...
- AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy
- AASLD 2015: HCV Triple Regimen Cures Rapid Responders in 3 Weeks
- AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
- AASLD 2015: Daclatasvir + Sofosbuvir Works Well for Genotype 3 HCV Patients with Advanced Disease
- AASLD 2015: MiR-122 Inhibitor RG-101 Suppresses Hepatitis C Virus with Single Dose
- AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate
- AASLD 2015: Grazoprevir/ Elbasvir Cures More than 90% of People with HIV/HCV Coinfection
- AASLD 2015: Intensification with Sofosbuvir Permits Cure after Previous HCV Treatment Failure
- AASLD 2015: Sofosbuvir/ Ledipasvir + Vedroprevir Cures 96% of Cirrhotic Genotype 1 Patients
- AASLD 2015: New AbbVie Hepatitis C Combination Cures Up to 97% with Genotype 3
- AASLD 2015: Sofosbuvir + Ravidasvir Shows High Response Rates for Genotype 4 Hepatitis C
- AASLD 2015: New AbbVie Pangenotypic Regimen Cures 97%-100% of Hepatitis C Patients in Early Study
- AASLD 2015: Sofosbuvir/ Velpatasvir Shows High Cure Rates for All HCV Genotypes in Phase 3
- AASLD 2015: Sofosbuvir/ Velpatasvir + GS-9857 for 8 Weeks Cures Most Genotype 1 or 3 Hepatitis C Patients
- AASLD 2015: Grazoprevir/ Elbasvir Shows High Cure Rate for People Who Inject Drugs
- AASLD 2015: HCV Infection During Anal Sex May Happen without Blood, Study Finds
- AASLD 2015: Liver Fibrosis Improves after Successful Treatment for Chronic Hepatitis C
- AASLD 2015: Sofosbuvir Plus Ribavirin Shows Suboptimal Efficacy for Acute Hepatitis C
- AASLD 2015: People with Cirrhosis Cured of Hepatitis C Still Have Elevated Liver Cancer Risk
- AASLD 2015: Clinical Impact of DAAS -- Referrals for Liver Transplants Drop
- AASLD 2015: Almost Half of U.S. Medicaid Recipients Denied Funding for Hepatitis C Treatment
- AASLD 2015: Liver Doctors and Advocates Call for Wider Treatment of People with Hepatitis C
Web Design and Development by